Literature DB >> 8789380

Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs.

R Verheggen1, S Freudenthaler, F Meyer-Dulheuer, A J Kaumann.   

Abstract

1. We investigated the hypothesis that, as in some other large human arteries, 5-HT-induced contraction of the temporal artery is mediated through two co-existing receptor populations, 5-HT1-like- and 5-HT2A. Temporal arterial segments were obtained from patients undergoing brain surgery and rings prepared set up to contract with 5-HT and related agents. Fractions of maximal 5-HT responses mediated through 5-HT1-like and 5-HT2A receptors, f1 and f2 = 1-f1, were estimated by use of the 5-HT2A-selective antagonist ketanserin. 2. In rings with intact endothelium 5-HT evoked contractions with a -log EC50, M of 7.0. Ketanserin (10-1000 nM) antagonized part of the 5-HT-induced contractions. Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M of 6.9 and f1 of 0.17 (100 nM ketanserin) and -log EC50, M of 6.4 and f1 of 0.20 (1000 nM ketanserin). 3. In rings with endothelial function attenuated by enzymatic treatment, 5-HT caused contractions with a -log EC50, M of 7.2 that were partially blocked by ketanserin. Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M 7.4 and f1 of 0.16 (100 nM ketanserin) and -log EC50, M of 7.5 and f1 of 0.14 (1000 nM ketanserin). 4. The ketanserin-resistant component of 5-HT-evoked contraction was blocked by methiothepin (100-1000 nM) consistent with mediation through 5-HT1-like receptors. 5. In rings with intact endothelium the 5-HT1-like-selective agonist, sumatriptan, caused small contractions with a -log EC50, M of 6.5 and intrinsic activity of 0.21 with respect to 5-HT that were resistant to blockade by 1000 nM ketanserin but antagonized by 100 nM methiothepin. 6. In rings with intact endothelium the 5-HT2A receptor partial agonist SK&F 103829 (2,3,4,5-tetrahydro-8[methyl sulphonyl]-1H3-benzazepin-7-ol methensulphonate) contracted rings with a -log EC50, M of 5.0 and an intrinsic activity of 0.49 with respect to 5-HT; the effects were antagonized by ketanserin 1000 nM. 7. We conclude that 80-86% of the maximum 5-HT-evoked contraction of human temporal artery is mediated through 5-HT2A receptors, the remainder through 5-HT1-like-receptors, regardless of whether or not endothelium is functional. The 5-HT1-like-receptors are more likely to be 5-HT1D beta receptors than 5-HT1D alpha receptors and sumatriptan is a full agonist for these receptors. As found in arteries of other species, SK&F 103829 is a partial agonist for 5-HT2A receptors of human temporal artery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789380      PMCID: PMC1909269          DOI: 10.1111/j.1476-5381.1996.tb15188.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.

Authors:  T Branchek; N Adham; M Macchi; H T Kao; P R Hartig
Journal:  Mol Pharmacol       Date:  1990-11       Impact factor: 4.436

2.  New mouse 5-HT2-like receptor. Expression in brain, heart and intestine.

Authors:  S Loric; J M Launay; J F Colas; L Maroteaux
Journal:  FEBS Lett       Date:  1992-11-09       Impact factor: 4.124

3.  [125I]LSD labels 5-HT1C recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding.

Authors:  D Hoyer; S Srivatsa; A Pazos; G Engel; J M Palacios
Journal:  Neurosci Lett       Date:  1986-09-12       Impact factor: 3.046

4.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

Review 5.  Serotonin and migraine.

Authors:  P P Humphrey; W Feniuk; M J Perren; I J Beresford; M Skingle; E T Whalley
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 6.  5-HT2 receptor antagonists and migraine therapy.

Authors:  E J Mylecharane
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

7.  5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries.

Authors:  A H Chester; G R Martin; M Bodelsson; B Arneklo-Nobin; S Tadjkarimi; K Tornebrandt; M H Yacoub
Journal:  Cardiovasc Res       Date:  1990-11       Impact factor: 10.787

8.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

9.  Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

10.  The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

Authors:  D W Bonhaus; C Bach; A DeSouza; F H Salazar; B D Matsuoka; P Zuppan; H W Chan; R M Eglen
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

View more
  10 in total

1.  BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37).

Authors:  Raphaela Verheggen; Katja Bumann; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 2.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry.

Authors:  T Nilsson; J Longmore; D Shaw; I J Olesen; L Edvinsson
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs.

Authors:  I Carel; B Ghaleh; A Edouard; J L Dubois-Rande; A A Parsons; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

5.  BIBN4096BS and CGRP(8-37) antagonize the relaxant effects of alpha-CGRP more than those of beta-CGRP in human extracranial arteries.

Authors:  Raphaela Verheggen; Kordian Wojtas; Martin Webel; Steffi Hoffmann; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-06-28       Impact factor: 3.000

6.  Functional 5-HT receptors in human occipital artery.

Authors:  Raphaela Verheggen; Andreas Meier; Inga Werner; Andreas Wienekamp; Thomas Kruschat; Trond Brattelid; Finn Olav Levy; Alberto Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-03-06       Impact factor: 3.000

7.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.

Authors:  Z Razzaque; M A Heald; J D Pickard; L Maskell; M S Beer; R G Hill; J Longmore
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

8.  5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan.

Authors:  Z Razzaque; J D Pickard; Q-P Ma; D Shaw; K Morrison; T Wang; J Longmore
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

9.  Genetic Variants Underlying Risk of Intracranial Aneurysms: Insights from a GWAS in Portugal.

Authors:  Patrícia Abrantes; Maria M Santos; Inês Sousa; Joana M Xavier; Vânia Francisco; Tiago Krug; João Sobral; Mafalda Matos; Madalena Martins; António Jacinto; Domingos Coiteiro; Sofia A Oliveira
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

10.  Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.

Authors:  J Longmore; Z Razzaque; D Shaw; A P Davenport; J Maguire; J D Pickard; W N Schofield; R G Hill
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.